Clinical Trials in the UK / NCT03899155

Recruiting Phase 2

Pan Tumor Rollover Study

NCT03899155 · tracked via the Priya Life Science UK tracker

Sponsor

Bristol-Myers Squibb

Phase

Phase 2

Started

2019-08-09

Last updated

2026-07-29

Condition(s) studied

Cancer

Investigational drug(s) / intervention(s)

NivolumabIpilimumabCabozantinibTrametinibRelatlimabNivolumab + RelatlimabCapecitabineBevacizumabTemozolomideRucaparibDaratumumabRegorafinibLeucovorinFluorouracilOxaliplatinEnzalutamideSunitinibPemetrexedPembrolizumab

Nivolumab: Specified dose on specified days

Ipilimumab: Specified dose on specified days

Cabozantinib: Specified dose on specified days

Trametinib: Specified dose on specified days

Relatlimab: Specified dose on specified days

Nivolumab + Relatlimab: Specified dose on specified days

Capecitabine: Specified dose on specified days

Bevacizumab: Specified dose on specified days

Temozolomide: Specified dose on specified days

Rucaparib: Specified dose on specified days

Daratumumab: Specified dose on specified days

Regorafinib: Specified dose on specified days

Leucovorin: Specified dose on specified days

Fluorouracil: Specified dose on specified days

Oxaliplatin: Specified dose on specified days

Enzalutamide: Specified dose on specified days

Sunitinib: Specified dose on specified days

Pemetrexed: Specified dose on specified days

Pembrolizumab: Specified dose on specified days

Study summary

Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria * Signed Written Informed Consent. * Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study. * On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study. * WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF. Exclusion Criteria * Participant is not eligible for study treatment per the Parent Study eligibility criteria. * Participants not receiving clinical benefit as assessed by the Investigator. * Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant. * Other protocol-defined Inclusion/Exclusion Criteria apply

Primary outcome measure(s)

Incidence of Adverse Events (AEs) — From Day 1 up to 135 Days after discontinuation of treatment
Incidence of drug related AEs — From Day 1 up to 135 Days after discontinuation of treatment
Incidence of AEs leading to Discontinuation — From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Serious Adverse Events (SAEs) — From signature of Informed Consent up to 135 Days after discontinuation of treatment
Incidence of Select AEs — From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Immune-Mediated AEs — From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Death — From signature of Informed Consent up to 135 Days after discontinuation of treatment

Trial sites (399)

Facility	City	Region	Status
Local Institution - 0220	Huntsville	Alabama	Completed
University of Arizona College of Medicine	Tucson	Arizona	Withdrawn
Innovative Clinical Research Institute	Lynwood	California	Withdrawn
Local Institution	San Francisco	California	Withdrawn
Local Institution - 0099	San Francisco	California	Completed
Local Institution - 0233	Aurora	Colorado	Completed
Local Institution - 0095	New Haven	Connecticut	Withdrawn
Local Institution - 0088	Washington D.C.	District of Columbia	Completed
Florida Cancer Affiliates	Ocala	Florida	Withdrawn
Local Institution	Orlando	Florida	Withdrawn
Local Institution - 0024	Tampa	Florida	Completed
Local Institution - 0105	Chicago	Illinois	Completed
Local Institution	Maywood	Illinois	Withdrawn
Local Institution - 0279	Park Ridge	Illinois	Completed
Local Institution - 0186	Westwood	Kansas	Completed
Local Institution - 0165	Wichita	Kansas	Completed
University of Louisville-James Graham Brown Cancer Center	Louisville	Kentucky	Recruiting
Local Institution - 0092	Baltimore	Maryland	Completed
Local Institution - 0039	Boston	Massachusetts	Completed
Dana_Farber Cancer Institute (DFCI)	Boston	Massachusetts	Recruiting
Local Institution - 0081	Boston	Massachusetts	Withdrawn
Local Institution - 0143	Ann Arbor	Michigan	Completed
Local Institution - 0100	Minneapolis	Minnesota	Completed
Local Institution	St Louis	Missouri	Withdrawn
Local Institution - 0205	Omaha	Nebraska	Completed
Local Institution - 0014	Lebanon	New Hampshire	Completed
Local Institution	Albuquerque	New Mexico	Withdrawn
Local Institution - 0128	Buffalo	New York	Completed
NYU Langone Hematology Oncology Associates-Mineola	Mineola	New York	Recruiting
Local Institution	New York	New York	Withdrawn
Local Institution - 0185	New York	New York	Completed
Local Institution - 0202	New York	New York	Withdrawn
Local Institution	New York	New York	Withdrawn
Local Institution - 0204	Charlotte	North Carolina	Completed
Local Institution - 0016	Durham	North Carolina	Completed
Oncology Hematology Care	Cincinnati	Ohio	Recruiting
Local Institution - 0408	Cincinnati	Ohio	Completed
Local Institution	Cleveland	Ohio	Withdrawn
The Ohio University	Columbus	Ohio	Recruiting
Local Institution - 0246	Tulsa	Oklahoma	Withdrawn

+ 359 more sites — see the full list on the official registry below.

On this site

📄 Opdivo (nivolumab) drug profile → 📄 Cabometyx (cabozantinib) drug profile → 📄 Avastin (bevacizumab) drug profile → 📄 Rubraca (rucaparib) drug profile → 📄 Darzalex (daratumumab) drug profile → 📄 Xtandi (enzalutamide) drug profile → 📄 Keytruda (pembrolizumab) drug profile →

More Bristol-Myers Squibb trials in the UK

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Recruiting

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma Recruiting

Other trials for the same condition

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab Enrolling by invitation

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer Active, not recruiting

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Active, not recruiting

Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial Active, not recruiting

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03899155 on ClinicalTrials.gov ↗ ← All trials in the UK